Jose P. López-Atalaya
@jplopez-atalaya.bsky.social
Neuroscientist at Spanish National Research Council (CSIC) @csic.es - Instituto de Neurociencias (UMH-CSIC) @neuroalc.bsky.social || https://in.umh-csic.es/en/grupos/cellular-plasticity-and-neuropathology/ || Sapere aude
Many congratulations, @lmprida.bsky.social All the best for this exciting new step ahead!
September 6, 2025 at 11:10 AM
Many congratulations, @lmprida.bsky.social All the best for this exciting new step ahead!
Reposted by Jose P. López-Atalaya
This therapy builds on research from Carlos Belmonte, @neuroviana.bsky.social and colleagues, who showed how corneal cold receptors drive tear production and identified TRPM8 as a target. Once again showcasing the international nature of scientific progress.
August 14, 2025 at 1:23 AM
This therapy builds on research from Carlos Belmonte, @neuroviana.bsky.social and colleagues, who showed how corneal cold receptors drive tear production and identified TRPM8 as a target. Once again showcasing the international nature of scientific progress.
Reposted by Jose P. López-Atalaya
It is also a vivid reminder of how difficult it is to translate a basic discovery into a useful therapy.
2002 cloning of TRPM8
2010 demonstration that TRPM8 sustains basal tearing
2024 COMET-2 and COMET-3 trials showed that M8 agonist significantly increased tear production
2025 FDA approves drug
2002 cloning of TRPM8
2010 demonstration that TRPM8 sustains basal tearing
2024 COMET-2 and COMET-3 trials showed that M8 agonist significantly increased tear production
2025 FDA approves drug
August 16, 2025 at 10:16 AM
It is also a vivid reminder of how difficult it is to translate a basic discovery into a useful therapy.
2002 cloning of TRPM8
2010 demonstration that TRPM8 sustains basal tearing
2024 COMET-2 and COMET-3 trials showed that M8 agonist significantly increased tear production
2025 FDA approves drug
2002 cloning of TRPM8
2010 demonstration that TRPM8 sustains basal tearing
2024 COMET-2 and COMET-3 trials showed that M8 agonist significantly increased tear production
2025 FDA approves drug